<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle18
{mso-style-type:personal;
font-family:Palatino;
color:windowtext;
font-weight:normal;
font-style:normal;}
span.EmailStyle19
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:1303922089;
mso-list-template-ids:1930851338;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1
{mso-list-id:1542596998;
mso-list-template-ids:1733970800;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2
{mso-list-id:1627003816;
mso-list-template-ids:1132229030;}
@list l2:level1
{mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l2:level2
{mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l2:level3
{mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l2:level4
{mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l2:level5
{mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l2:level6
{mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l2:level7
{mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l2:level8
{mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l2:level9
{mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l3
{mso-list-id:2074573258;
mso-list-template-ids:852014108;}
@list l3:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l3:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-20-006.html__;!!PhOWcWs!lDEj-6gJlSyeeb9yyw8efVpXWeWKJuyObYeO5FSbbjPAtyr_K8A9QlBO-VL9Ed10fSKP0pl_a8IFkgkrDVc$" target="_blank">BRAIN Initiative: Biology and Biophysics of Neural Stimulation and Recording Technologies (R01 Clinical Trials
Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">A central goal of the BRAIN Initiative is to develop new and improved technologies suitable for recording from as well as controlling specified cell types and circuits to modulate and understand function
in the central nervous system. In order to accomplish these goals, further information is needed to understand the function of current technologies used for recording or stimulating the nervous system.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">This RFA accepts grant applications in two related but distinct areas. The first is to systematically characterize, model, and validate the membrane, cellular, circuit, and adaptive-biological responses
of neuronal and non-neuronal cells to various types of stimulation technologies. The second is to understand the biological and bioinformatic content of signals recorded from neuronal and non-neuronal cells and circuits. Development of new technologies, therapies
and disease models is outside the scope of this FOA. Activities related to enabling the simultaneous use of multiple recording or stimulation technologies are allowed.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due March 24, 2020; June 2, 2020; October 1, 2020; February 2, 2021; June 1, 2021; October 1, 2021; February 1, 2022; June 1, 2022; and October 3, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for March 2020 deadline: March 11.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Mechanisms of Disparities in Chronic Liver Diseases and Cancer (R21 / R01 - Clinical Trial Not Allowed)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-081.html__;!!PhOWcWs!lDEj-6gJlSyeeb9yyw8efVpXWeWKJuyObYeO5FSbbjPAtyr_K8A9QlBO-VL9Ed10fSKP0pl_a8IF7UkkO7U$" target="_blank">R21</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/par-20-088.html__;!!PhOWcWs!lDEj-6gJlSyeeb9yyw8efVpXWeWKJuyObYeO5FSbbjPAtyr_K8A9QlBO-VL9Ed10fSKP0pl_a8IFu8Oposo$" target="_blank">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The purpose of these initiatives is to support multidisciplinary research to understand the underlying etiologic factors and mechanisms that contribute to population-level disparities in chronic liver
diseases and liver cancer in the U.S.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due April 1, 2020; April 1, 2021; and April 1, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for April 2020 deadline: March 19.</span></span></b><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.alzdiscovery.org/research-and-grants/funding-opportunities/prevention-beyond-the-pipeline__;!!PhOWcWs!lDEj-6gJlSyeeb9yyw8efVpXWeWKJuyObYeO5FSbbjPAtyr_K8A9QlBO-VL9Ed10fSKP0pl_a8IFC0om2U8$" target="_blank">Alzheimer's Drug Discovery Foundation: Prevention Beyond the Pipeline</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive
decline. Specifically, the Prevention Beyond the Pipeline RFP supports:<o:p></o:p></span></p>
<ol style="margin-top:0in" start="1" type="1">
<li class="MsoNormal" style="mso-list:l2 level1 lfo1"><span style="font-family:Palatino">Studies Leveraging the Consortium of Cohorts for Alzheimer's Prevention Action (CAPA): Epidemiological studies contribute unmatched information on whether the risk of dementia
or cognitive decline may be influenced by long-term exposure to specific foods or supplements. However, high-powered studies are needed, ideally with dose, duration, and responder profiles, in order to translate epidemiological research into actionable interventions
for testing. Through the CAPA Consortium, the ADDF funds collaborative analyses on dementia prevention using a minimum of five longitudinal cohorts, either harmonized or analyzed through parallel analysis of cohorts using a shared analysis script.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo1"><span style="font-family:Palatino">Comparative Effectiveness Research: For many health conditions, physicians have a choice of clinically equivalent drugs. Some of these drugs are being investigated for
repurposing to treat Alzheimer's or related dementias, due to potential disease-modifying properties that go beyond the treatment of their approved disease indication. The ADDF will consider funding research to generate an evidence base on whether choices
in the routine clinical care of pre-existing conditions could protect from dementia. Priority will be given to the comparison of drugs that are otherwise clinically equivalent for the pre-existing condition. Methods may include randomized trials or epidemiology.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo1"><span style="font-family:Palatino">Studies of Cognitive Decline and Cognitive Reserve: Cognitive decline through aging and health conditions has been linked to an increased risk of dementia. The ADDF will
consider funding programs to prevent and treat these conditions, including cognitive aging, menopause-related cognitive symptoms, postoperative delirium and postoperative cognitive decline, mild and/or repetitive traumatic brain injury, and chemotherapy-induced
decline. Methods may include epidemiology or clinical trials. For clinical trial proposals, please see below detailed instructions and priorities under “Funding Priorities for Clinical Trial Proposals” and “Evaluation of Clinical Trial Proposals”.<o:p></o:p></span></li></ol>
<p class="MsoNormal"><span style="font-family:Palatino">Current target areas of interest include epigenetics, inflammation, mitochondria and metabolic function, neuroprotection, proteostasis, synaptic activity and neurotransmitters, vascular function, other
aging targets (e.g., senescent cells), and other novel targets or pathways that are supported by compelling evidence demonstrating a rational biological connection to age-related cognitive decline or dementia risk.
<b>Average duration:</b> One year for epidemiological analyses. Varies (multi-year) for clinical trials.
<b>Average Award:</b> $50,000-$100,000 for epidemiological analyses based on scope of research. Up to $3 million for clinical trials based on stage and scope of research.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Letter of intent due April 10, July 10, and October 9, 2020.
<span style="color:red">Med-RA deadline to receive draft documents for April 2020 deadline: March 30.</span></span></b><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.alzdiscovery.org/research-and-grants/funding-opportunities/drug-development-program__;!!PhOWcWs!lDEj-6gJlSyeeb9yyw8efVpXWeWKJuyObYeO5FSbbjPAtyr_K8A9QlBO-VL9Ed10fSKP0pl_a8IFLN1HKXI$" target="_blank">Alzheimer's Drug Discovery Foundation: Drug Development Program</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The goal of this RFP is to develop therapeutics for Alzheimer's disease and related dementias. This RFP focuses on building preclinical evidence in animal models and on advancing lead molecules to the
clinical candidate selection stage. The proposed studies should have a high probability of reaching IND-enabling studies within two years.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Specifically, the Drug Development RFP supports:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l3 level1 lfo2"><span style="font-family:Palatino">Preclinical pharmacokinetics, pharmacodynamics, target engagement, and preliminary rodent tolerability<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo2"><i><span style="font-family:Palatino">In</span></i><span style="font-family:Palatino">
<i>vivo</i> efficacy or proof-of-concept studies<o:p></o:p></span></li></ul>
<p class="MsoNormal"><i><span style="font-family:Palatino">Applications that focus on basic science, target identification, target validation, assay development, and high-throughput screening are not a priority for this RFP and will be withdrawn.</span></i><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The ADDF is interested in small molecules and biologics (e.g. antibodies, peptides, gene therapies). Both novel programs and repurposing/repositioning of approved or clinically safe therapies from other
disease indications are appropriate for this RFP. Current target areas of interest include epigenetics, inflammation, mitochondria and metabolic function, neuroprotection, proteostasis, synaptic activity and neurotransmitters, vascular function, other aging
targets (e.g., senescent cells), and other novel targets or pathways that are supported by compelling evidence demonstrating a rational biological connection to the disease process <o:p></o:p></span></p>
<p class="MsoNormal"><i><span style="font-family:Palatino">This RFP does not support anti-amyloid approaches (e.g., anti-amyloid aggregation, beta-amyloid vaccines, beta- or gamma-secretase inhibitors) or cholinesterase inhibitors.</span></i><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Average Duration: </span>
</b><span style="font-family:Palatino">One year with potential for follow-on funding. Multi-year proposals can be considered.
<b>Average Award: </b>$150,000-$600,000 based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Letter of intent due April 10, 2020; July 10, 2020; and October 9, 2020.
<span style="color:red">Med-RA deadline to receive draft documents for April 2020 deadline: March 30.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/rfa-hg-20-007.html__;!!PhOWcWs!lDEj-6gJlSyeeb9yyw8efVpXWeWKJuyObYeO5FSbbjPAtyr_K8A9QlBO-VL9Ed10fSKP0pl_a8IFA4-BuL0$" target="_blank">Mendelian Genomics Research Centers (U01 - Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The purpose of this Funding Opportunity is to establish a consortium aimed at significantly increasing the proportion of Mendelian conditions with an identified genetic cause. A key objective of the Mendelian
Genomics Research Centers is to develop and apply approaches to discover causal genes underlying Mendelian conditions for which a candidate gene was not identified using whole exome sequencing alone.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due April 15, 2020. <span style="color:red">
Med-RA deadline to receive draft documents: April 2.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Research Answers to National Cancer Institute’s (NCI) Provocative Questions (R21 / R01 Clinical Trial Optional)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/rfa-ca-20-005.html__;!!PhOWcWs!lDEj-6gJlSyeeb9yyw8efVpXWeWKJuyObYeO5FSbbjPAtyr_K8A9QlBO-VL9Ed10fSKP0pl_a8IFI8tOiHI$" target="_blank">R21</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/rfa-ca-20-004.html__;!!PhOWcWs!lDEj-6gJlSyeeb9yyw8efVpXWeWKJuyObYeO5FSbbjPAtyr_K8A9QlBO-VL9Ed10fSKP0pl_a8IF-Vn0BF8$" target="_blank">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The purpose of these Funding Opportunity Announcements (FOAs) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute
(NCI) Provocative Questions Initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI’s priorities in cancer research. Rather, they are meant to challenge researchers to think about and elucidate specific
problems in key areas of cancer research that are deemed important but have not received sufficient attention.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Some of these “Provocative Questions” (PQs) stem from intriguing but older, neglected observations that have never been adequately explored. Other PQs are built on more recent findings that are perplexing
or paradoxical, revealing important gaps in current knowledge. Finally, some PQs reflect problems that traditionally have been thought to be intractable but that now may be open to investigations using new strategies and recent technical advances.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The current issuance of the PQ Initiative includes an updated set of 9 PQs. Each research project proposed in response to these FOAs must be focused on addressing the research problems defined by a specific
PQ selected from the list. Projects proposed to address PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged if they serve the scientific focus of the selected PQ.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">PQs:</span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l0 level1 lfo3"><span style="font-family:Palatino">What are the underlying causes of the unexplained rising incidence in early-onset cancers?<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo3"><span style="font-family:Palatino">How does intermittent fasting affect cancer incidence, treatment response, or outcome?<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo3"><span style="font-family:Palatino">How do selective pressures affect cell competition and cooperation during cancer initiation and development?<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo3"><span style="font-family:Palatino">What mechanisms explain sex differences in cancer incidence, lesion location, or response to therapy?<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo3"><span style="font-family:Palatino">What strategies can block or reverse the emergence of new cell lineage states induced by cancer treatments?<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo3"><span style="font-family:Palatino">How can cancer cachexia be reversed?<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo3"><span style="font-family:Palatino">What methods can be developed to integrate patient-generated health data into electronic health records?<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo3"><span style="font-family:Palatino">What strategies improve and sustain coordination of comprehensive healthcare for underserved cancer patients with comorbidities?<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo3"><span style="font-family:Palatino">What methods can be developed to effectively study small or rare populations relevant to cancer research?<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due April 30, 2020 and November 17, 2020.
<span style="color:red">Med-RA deadline to receive draft documents for April 2020 deadline: April 20.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-077.html__;!!PhOWcWs!lDEj-6gJlSyeeb9yyw8efVpXWeWKJuyObYeO5FSbbjPAtyr_K8A9QlBO-VL9Ed10fSKP0pl_a8IFLGESovQ$" target="_blank">National Cancer Institute Program Project Applications (P01 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">With this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for investigator-initiated Program Project (P01) applications. The proposed Program may address
any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas
are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Standard dates apply. Expires May 8, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for May 25, 2020 standard date: May 11.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-095.html__;!!PhOWcWs!lDEj-6gJlSyeeb9yyw8efVpXWeWKJuyObYeO5FSbbjPAtyr_K8A9QlBO-VL9Ed10fSKP0pl_a8IFHxKFNgw$" target="_blank">Development of Research Education Resources for Geriatrics-Related Translational and Clinical Scientists (R25 Independent
Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this R25 program is to support educational activities that complement
and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated overarching goal, this FOA will support creative educational activities with a primary focus on the following:<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Curriculum or Methods Development:</span></b><span style="font-family:Palatino"> This FOA is intended to support the development of a multi-disciplinary clinical and translational geriatrics-related
research curriculum that will be used in future training programs for clinician-scientists. Such resource development will fill a need not currently addressed by existing NIH- and NIA-supported programs. Proposed resources should improve geriatrics research
education through innovative programs, novel instructional approaches, computer-based tools, problem-based learning, and other effective strategies. Specific research education topics may include, but are not limited to, the following:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l1 level1 lfo4"><span style="font-family:Palatino">Scientific approaches to prevention and management of multimorbidity<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo4"><span style="font-family:Palatino">Clinical investigation and clinical trials of geroscience-related interventions<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo4"><span style="font-family:Palatino">Development and incorporation of functional outcomes into clinical studies<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo4"><span style="font-family:Palatino">Research approaches toward treatment of geriatric conditions and disease management within a geriatric framework<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo4"><span style="font-family:Palatino">Recruitment of diverse populations of older adults into clinical research studies<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo4"><span style="font-family:Palatino">Research approaches to geriatric health disparities<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-family:Palatino">Courses for Skills Development:</span></b><span style="font-family:Palatino"> In addition to development of a curriculum, this FOA can also support testing and refinement of the curriculum through courses.
Such implementation, if proposed, is expected in the latter years of the R25 award.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Research Experiences:</span></b><span style="font-family:Palatino"> If warranted, this FOA can also support hands-on research experiences for the purposes of testing and refining the curriculum in the
latter years of the R25 award.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Standard dates apply. Expires January 26, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for May 25, 2020 standard date: May 11.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-093.html__;!!PhOWcWs!lDEj-6gJlSyeeb9yyw8efVpXWeWKJuyObYeO5FSbbjPAtyr_K8A9QlBO-VL9Ed10fSKP0pl_a8IFuvJ39K0$" target="_blank">Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research (P50 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">This Funding Opportunity Announcement (FOA) encourages applications for Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research. The NIMH seeks teams of researchers working
at different levels of analysis and employing integrative, novel, and creative experimental approaches to address high-risk, high-impact questions with the primary objectives of: (a) advancing the state of the science in basic brain and behavior research that
will uncover and dissect the underlying mechanisms that will ultimately provide the foundation for understanding mental disorders; (b) supporting the integration and translation of basic and clinical neuroscience research on severe mental illnesses; and/or
(c) advancing our understanding of the neurobehavioral developmental mechanisms and trajectories of psychopathology that begin in childhood and adolescence. The Conte Centers program is intended to support interdisciplinary basic neuroscience or translational
research that demonstrates an extraordinary level of synergy, integration, and potential for advancing the state of the field. This program is intended only for projects that could not be achieved using other, more standard grant mechanisms.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due May 27, 2020; May 26, 2021; and May 24, 2022. <span style="color:red">Med-RA deadline to receive draft documents for May 2020 deadline: May 13.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-072.html__;!!PhOWcWs!lDEj-6gJlSyeeb9yyw8efVpXWeWKJuyObYeO5FSbbjPAtyr_K8A9QlBO-VL9Ed10fSKP0pl_a8IFQ1FcTzQ$" target="_blank">NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated Program Project (P01) applications. The proposed programs may address scientific areas relevant to the NIAID mission
including the biology, pathogenesis, and host response to microbes, including HIV; the mechanisms of healthy immune system development and function across the lifespan; and immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, and
transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious and immune-mediated diseases. Each P01 application submitted to this FOA must include at least two related, synergistic research
projects that share a common central theme, focus, and/or overall objective; and an administrative core. A P01 may include scientific cores, if needed for proposed research.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due June 11, 2020; January 11, 2021; June 11, 2021; January 11, 2022; and June 10, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for June 2020 deadline: May 13.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"> <o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-21-010.html__;!!PhOWcWs!lDEj-6gJlSyeeb9yyw8efVpXWeWKJuyObYeO5FSbbjPAtyr_K8A9QlBO-VL9Ed10fSKP0pl_a8IFT6AtCDM$" target="_blank">Glial Plasticity in the Aging Brain (R01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Recent reports highlight the enormous spatial and temporal diversity of glia, even within the same glial cell type. This within-glial-cell-type heterogeneity evolves during aging, suggesting that subtypes
of glia with distinct physiological roles could emerge to influence brain aging processes. The goal of this Funding Opportunity Announcement is to support research addressing critical knowledge gaps in our understanding of how these glial subpopulations could
contribute to vulnerability and resilience to brain aging.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due June 17, 2020. <span style="color:red">
Med-RA deadline to receive draft documents: June 4.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-21-002.html__;!!PhOWcWs!lDEj-6gJlSyeeb9yyw8efVpXWeWKJuyObYeO5FSbbjPAtyr_K8A9QlBO-VL9Ed10fSKP0pl_a8IFRK797rE$" target="_blank">Mechanisms of Rejuvenation and Age-Acceleration in Heterochronic Blood Exchange (R01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">This FOA will support research on aspects of rejuvenation and accelerated aging observed specifically in heterochronic blood exchange (HBE) experiments. The objectives are to identify the multiple factors
involved, the multiple cell types involved, and the mechanisms underlying rejuvenation or accelerated aging that are observed in the transfer of phenotypes between young and old laboratory animals. It is also anticipated that molecular signatures of rejuvenation
or accelerated aging will be obtained from research supported under this FOA.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due June 17, 2020. <span style="color:red">
Med-RA deadline to receive draft documents: June 4.<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=8671&WT.mc_id=USNSF_39&WT.mc_ev=click__;!!PhOWcWs!lDEj-6gJlSyeeb9yyw8efVpXWeWKJuyObYeO5FSbbjPAtyr_K8A9QlBO-VL9Ed10fSKP0pl_a8IFTDv1swI$" target="_blank">NSF: Developmental Sciences (DS)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">DS supports basic research that increases our understanding of cognitive, linguistic, social, cultural, and biological processes related to human development across the lifespan. Research supported by
this program will add to our knowledge of the underlying developmental processes that support social, cognitive, and behavioral functioning, thereby illuminating ways for individuals to live productive lives as members of society. DS supports research that
addresses developmental processes within the domains of cognitive, social, emotional, and motor development across the lifespan by working with any appropriate populations for the topics of interest including infants, children, adolescents, adults, and non-human
animals. The program also supports research investigating factors that affect developmental change including family, peers, school, community, culture, media, physical, genetic, and epigenetic influences. Additional priorities include research that: incorporates
multidisciplinary, multi-method, microgenetic, and longitudinal approaches; develops new methods, models, and theories for studying development; includes participants from a range of ethnicities, socioeconomic backgrounds, and cultures; and integrates different
processes (e.g., memory, emotion, perception, cognition), levels of analysis (e.g., behavioral, social, neural), and time scales. The budgets and durations of supported projects vary widely and are greatly influenced by the nature of the project. Investigators
should focus on innovative, potentially transformative research plans and then develop a budget to support those activities, rather than starting with a budget number and working up to that value. While there are no specific rules about budget limitations,
a typical project funded through the DS program is approximately 3 years in duration with a total cost budget, including both direct and indirect costs, between $100,000 and $200,000 per year.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due July 15, 2020. January 15 and July 15 annually thereafter.
<span style="color:red">Med-RA deadline to receive draft documents for July 2020 deadline: July 1.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=5712&WT.mc_id=USNSF_39&WT.mc_ev=click__;!!PhOWcWs!lDEj-6gJlSyeeb9yyw8efVpXWeWKJuyObYeO5FSbbjPAtyr_K8A9QlBO-VL9Ed10fSKP0pl_a8IF-_WlwDA$" target="_blank">NSF: Social Psychology</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The Social Psychology Program at NSF supports research and research infrastructure to advance basic knowledge in social psychology. Projects funded by the Social Psychology Program support the NSF mission
to promote the progress of science; to advance the national health, prosperity, and welfare; and to secure the national defense. Proposed research should carry strong potential for creating transformative advances in the basic understanding of human social
behavior. Among the many research topics supported are: social cognition, attitudes, social and cultural influence, stereotypes, motivation, decision making, group dynamics, aggression, close relationships, social and affective neuroscience, social psychophysiology,
emotions, prosocial behavior, health-related behavior, and personality and individual differences. Proposals that develop new theories or methods for understanding social behavior are highly encouraged. Research samples should represent substantial ranges
of ethnicities, socioeconomic backgrounds, cultures, and other dimensions of human populations.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Proposals involving non-human animals are considered only if the research offers clear and direct contributions to understanding human social behavior. The program does not fund research that seeks to
improve clinical practice as its primary outcome, nor does it consider proposals with disease-related goals, including work on the etiology, diagnosis or treatment of physical or mental disease, abnormality, or malfunction in human beings or animals.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due July 15, 2020. January 15 and July 15 annually thereafter.
<span style="color:red">Med-RA deadline to receive draft documents for July 2020 deadline: July 1.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=5407&WT.mc_id=USNSF_39&WT.mc_ev=click__;!!PhOWcWs!lDEj-6gJlSyeeb9yyw8efVpXWeWKJuyObYeO5FSbbjPAtyr_K8A9QlBO-VL9Ed10fSKP0pl_a8IFiDBeMXo$" target="_blank">NSF: Biological Anthropology</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The Biological Anthropology Program supports basic research in areas related to human evolution and contemporary human biological variation. Research areas supported by the program include, but are not
limited to, human genetic variation, human and nonhuman primate ecology and adaptability, human osteology and bone biology, human and nonhuman primate paleontology, functional anatomy, and primate socioecology. Grants supported in these areas are united by
an underlying evolutionary framework, and often by a consideration of adaptation as a central theoretical theme. Proposals may also have a biocultural or bioarchaeological orientation. The program frequently serves as a bridge within NSF between the social
and behavioral sciences and the natural and physical sciences, and proposals commonly are jointly reviewed and funded with other programs.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due July 20, 2020. January 20 and July 20 annually thereafter.
<span style="color:red">Med-RA deadline to receive draft documents for July 2020 deadline: July 7.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">To search for additional funding opportunities, please visit </span></b><span style="font-family:Palatino;color:black"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=" title="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV69"><b><span style="color:red">CoM’s
unofficial funding opportunities blog</span></b></a></span><b><span style="font-family:Palatino;color:red">.</span></b><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
</div>
</body>
</html>